No Cellphone, Brain Cancer Link; Testosterone Paradox; Breast Density and Cancer

A WHO review of 63 studies found no evidence of an association between prolonged cellphone use and brain cancer. (Washington Post)

CDK4/6 inhibitors, best known for use in breast cancer, may have activity in a type of adolescent brain cancer. (Dana-Farber Cancer Institute, Cancer Cell)

Another win for artificial intelligence, this time for detection of immune-related adverse events related to cancer immunotherapy. (Mass General Brigham, Journal of Clinical Oncology)

New insights into testosterone’s paradoxical effects in prostate cancer. (Duke Health, Nature Communications)

A review of nearly 40 years of prostate cancer data showed rapid increases in incidence throughout Europe with little change in prostate cancer mortality, suggesting overdiagnosis. (The BMJ)

No tattoos or casual wear for oncologists — say oncologists. (Oncology News Central)

A class action lawsuit against Walgreens alleges the drugstore giant sold a generic version of the cold medicine Mucinex that contained the cancer-causing chemical benzene. (Reuters)

Questions about the FDA’s new regulation about breast density? The American College of Surgeons and the National Accreditation Program for Breast Centers have answers.

A comprehensive geriatric assessment can improve the chances that older patients with cancer receive optimal care, according to two recent publications. (University of Rochester Medical Center)

The search continues for an explanation for the puzzling rise in breast cancer incidence among Asian American and Pacific Islander women. (CBS News)

Staging for early pancreatic cancer might be inaccurate in nearly 80% of cases, emphasizing the need for better diagnostic and staging technology to help improve treatment and outcomes. (Cedars-Sinai Cancer, JAMA)

Please enable JavaScript to view the

comments powered by Disqus.